Oral Hypoglycaemic Agents (OHA): MOA and Drugs.pptx

910 views 23 slides Nov 19, 2022
Slide 1
Slide 1 of 23
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23

About This Presentation

This is a compact slide on Oral Hypoglycaemic Agents (drugs acting against diabetes, both type 1 and type 2) including its mechanism of action and drug examples.


Slide Content

Oral Hypoglycaemic Agents: MOA & Drugs Anirban Kumar Bora 17.11.2022 Assistant Professor Gitanjali College of Pharmacy Lohapur, Birbhum, West Bengal.

C ontents Sulphonylureas 01 Biguanides 02 Glinides 03 4 Thiazolidinediones Gliptins 5 6 α- Glucosidase Inhibitors Glucose Transport Inhibitors 7

01 Sulphonylureas

Drugs Tolbutamide Glyburide Gliclazide Glipizide Glimepiride 1st Generation: 2nd Generation:

1 Binds to specific receptors on β- cells of islets of Langerhans Mechanism of Action Stimulation of insulin release from β-cells of pancreas 2 Blocks ATP sensitive K + Channels 3 Depolarisation and influx of Ca 2+ ions into β-cells 4 Degranulation and exocytosis of stored insulin from β- cells

2 Biguanides

1 Directly or indirectly ↓ hepatic glucose production by inhibiting the mitochondrial respiratory chain complex I Drugs 2 ↑ in AMP which in turn activates AMP activated protein kinase (AMPK) 3 Triggers release of GLP-I 4 Stimulates gut- brain- liver vagal network (that regulates hepatic glucose production) Mechanism of Action Metformin

Ancillary Mechanism of Action ↑ G lucose uptake and utilisation in skeletal muscle ↓ C arbohydrate absorption from intestine ↓ C irculating low- density (LDL) and very low density lipoproteins (VLDL)

03 Gli nides

Repaglinide Nateglinide Stimulation of insulin release from β-cells of pancreas [Insulin secretagogue] Drugs Type of Mechanism

1 Binds to specific receptors on β- cells of islets of Langerhans Mechanism of Action 2 Closure of ATP sensitive K + Channels (known as SUR1 channel) 3 Depolarisation and influx of Ca 2+ ions into β-cells 4 Degranulation and exocytosis of stored insulin from β- cells Note Administered shortly before a meal to reduce postprandial rise in blood glucose in type 2 diabetes patients

04 Thiazolidinediones

Selective agonist for peroxisome proliferator- activated receptor γ (PPAR γ ) [a nuclear hormone receptor] Regulates transcription of several insulin responsive genes ↑ Sensitivity of insulin in peripheral tissue (including adipose tissue, liver, skeletal muscle) Drugs Pioglitazone Mechanism of Action

05 Gliptins

Sitagliptin Vildagliptin Drugs Saxagliptin Linagliptin Alogliptin

Inhibits enzyme DPP-4 (dipeptidyl peptidase 4) Stimulates insulin secretion Prevents inactivation of incretin hormones such as GLP-1 Mechanism of Action

06 α- Glucosidase Inhibitors

Acarbose Miglitol Drugs Voglibose

Reversibly inhibit α- glucosidase enzyme [ α- glucosidase enzymes break down carbohydrates into glucose and other simple sugars that can be absorbed] Delays digestion of carbohydrates, resulting in lower postprandial glucose Mechanism of Action

07 Glucose Transport Inhibitors

Canagliflozin Dapagliflozin Drugs Empagliflozin

Inhibits sodium- glucose cotransporter 2 (SGLT2) [SGLT2 is responsible for reabsorbing filtered glucose in the tubular lumen of the kidney] Promoting glucose excretion into the urine, thereby reducing the concentration of circulating glucose Mechanism of Action

THANK YOU!